Baxter International's (BAX) former kidney care segment Vantive said Monday it has been acquired by funds managed by Carlyle Group (CG).
Vantive will now operate as an independent organ therapy company, it added.
The deal was first announced by Baxter and Carlyle in August, under which Carlyle agreed to acquire Vantive for $3.8 billion.
Baxter shares were down 2.3% in recent Monday premarket activity, while Carlyle slipped 3%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.